Home / Transcripts / Prenetics Global Limited (PRE) · November 10, 2025

Prenetics Global Limited (PRE) Earnings Call Transcript

November 10, 2025

NASDAQ US Health Care Health Care Providers and Services earnings 24 min

Earnings Call Speaker Segments

Sheng Wu Yeung executive
#1

Thanks, and morning to everyone. For Prenetics, and for IM8 — the health and longevity brand we created together with David Beckham serving as co-founder — Q3 of 2025 marks a defining moment. Plenty of you already know that Prenetics has actually operated as a public company for several years now. Even so, this call is genuinely our inaugural quarterly earnings call. The simple reason for that: there was hardly any meaningful data worth pointing to, because our time went into a complete restructuring of how we operate. But now that our attention is fully centered on IM8 and the extraordinary growth trajectory it enjoys, we felt the right moment had arrived to begin engaging investors on a steadier cadence. Personally, my whole working life has gone into building companies that create their own categories; this is the fourth one I've started from nothing. My prior business was actually acquired by Groupon in Asia, and while I ran it, it grew into that region's largest direct-to-consumer e-commerce operation. After leaving Groupon, I started Prenetics about 11 years ago, focused on DNA testing. Then COVID hit, and we pivoted toward delivering PCR testing for the community. Over those 3 years alone, spanning 2020 to 2023, we generated over $800 million in revenue. That shows what we're capable of when it comes to executing — and executing at scale. As I wrote recently in my published manifesto, execution, as I see it, can be repeated. It boils down to recognizing inflection points early and building disciplined systems that convert vision into measurable results. That's exactly what we're doing at IM8. To me, this is a genuine once-in-a-lifetime opportunity to carve out a new category at the intersection of health and wealth. I believe IM8 can grow into one of the world's largest health and longevity brands, hitting $1 billion in annual revenue by 2030. That number may sound ambitious, but look at what we pulled off in just the last 9 months; we hit $100 million in annual recurring revenue within the last 11 months — a feat no one in the global supplement industry has ever managed. We also project $300 million ARR by the end of 2026. So for us, I see that as very, very realistic. Just last month, we closed a $44 million strategic funding round, bringing in a truly world-class group of investors, including Kraken, Exodus, XtalPi, and the World No.1 tennis champion, Aryna Sabalenka. Combined with the divestment of ACT Genomics, Prenetics currently holds roughly $120 million in total liquidity, $82 million in cash, 387 in Bitcoin worth approximately $40 million, and no debt. On top of that, we're carrying $6.5 million in additional resources. We think we're in a position of real strength to support accelerating growth. This capital also backs our dual engine growth model, where IM8 drives the health engine through rapid recurring revenue, and our Bitcoin treasury — which has acquired 1 BTC every day since August 1 — drives the wealth engine by safeguarding long-term value. Right now, Prenetics is the only consumer health company on NASDAQ that has placed Bitcoin on its balance sheet. Naturally, the next question is: why Bitcoin? I firmly believe that health and wealth are what lies ahead. In my manifesto, I also wrote that across the next ten years, prosperity will go to companies that merge the two — health provides purpose, and wealth provides staying power. Our Bitcoin strategy isn't a wager; it's one component of a resilient framework designed to generate enduring shareholder value alongside human well-being. Turning now to our Q2 results and IM8. Put plainly, the performance has been exceptional. Just 12 months after launch, IM8 is on pace to reach $120 million in annualized recurring revenue by December 2025 — the fastest growth trajectory ever recorded in the global supplement industry, beating even leading AI start-ups; in the third quarter, total revenue surged 568% year-over-year to $23.6 million, driven by IM8's 76% quarterly growth and rising international demand. October alone set a brand record with $9 million in monthly revenue, up 32% month-over-month, and it's on track to exceed $10 million in December. IM8 has achieved true global scale, with over 420,000 customer purchases across 31 countries worldwide. Notably, international markets now represent 56.5% of our total revenue, with the U.S. as our top market, followed by Canada, the U.K., Australia and Singapore; this geographic diversity validates our premium positioning across different markets. We're also uniquely positioned now to begin rolling out key performance indicators to better monitor IM8's growth and provide greater transparency into the brand's success. In the third quarter, our subscription rate was 80%. That means each time a new customer joins the platform, 80% of the time they become repeatable subscribers. Average order value also rose 36% quarter-over-quarter to $150. In the prior quarter, that figure was $110. Importantly, gross margin has increased to 60% from 52%, an 8% basis point improvement in just 1 quarter. Lastly, our customer payback period now stands at 3.9 months, churn included; what that tells you is we recover our customer acquisition costs in under 4 months. Typically, supplement brands see this figure around 6 to 12 months, and it shows we have very healthy unit economics and can continue scaling our marketing spend. What makes these results even more remarkable is that our growth has relied on essentially one SKU, the Daily Ultimate Essentials. That product effectively replaces 16 different supplements with one tasty drink. More recently, we launched Daily Ultimate Longevity in October, and this item is designed specifically to slow the aging process by targeting the 12 hallmarks of aging. Once we launched this product a month ago, it immediately lifted our average order value to $150 from $110, and it is entirely DTC. A 36% gain like that shows people are willing to pay a premium for solutions rooted in science, with quality and efficacy they can trust. What really excites me is how obviously we are heading toward breakeven and past it, into profitability. Consider our adjusted EBITDA loss: it was $4.5 million in Q1, improved to $4.1 million in Q2, and now in Q3 stands at only $2.1 million. Movement like that demonstrates we are capable of becoming profitable whenever we choose to be. Even so, given the enormous opportunity worldwide, we are intentionally choosing to push growth even harder. In our view, speed ultimately prevails. We have built a company centered on AI that can iterate, test, and scale at a tempo the legacy players just cannot keep up with. That is exactly why, in under 12 months, we reached a $120 million ARR run rate — something most other brands take 3 to 4 years to achieve. Add it all up, and IM8 will generate over $60 million in revenue across all of 2025, while for 2026 our full-year revenue guidance is $180 million to $200 million. So by the time 2026 ends, that means $25 million per month coming in, and $300 million in annual recurring revenue as 2026 closes and we head toward 2027, right? And keep in mind, this reflects only the IM8 brand — nothing from our other business units is in there. On top of that, we're looking at $6.5 million.

Sheng Wu Yeung executive
#2

To give you a sense of how we're growing, our trajectory looks a lot like what Hims & Hers experienced — going from $148 million to more than $2 billion in yearly revenue within only the past 5 years. Given that Grand View Research puts the worldwide supplements sector at over $700 billion by 2030, we've barely begun to capture the market available to us. What makes me confident about these numbers is how strong the data is that we hold today, with 3 complete quarters of IM8 data, and that data is quite clear and convincing; we think the flywheel is now in place. At the same time, and this matters, we've kicked off a strategic review of noncore assets — Europa Sports, CircleDNA and Insighta — after a successful $72 million sale of ACT Genomics. As a matter of fact, we're in the final stages of divesting Europa and an announcement will come in the next few weeks. This kind of focus shows another benefit of executing the manifesto rather than ideology. We're streamlining our structure so that every resource goes toward our highest margin and fastest-growing engine, which is IM8. Thanks to our partnerships with David Beckham, Co-Founder of IM8, and Aryna Sabalenka, the World No.1 tennis player, we've gained worldwide visibility that few rivals can equal. On the operational side, our Scientific Advisory Board — 11 world-class experts from places such as the Mayo Clinic and Cedars-Sinai — underpins our brand credibility and innovation. IM8 operates as a 100% direct-to-consumer brand, and this data-driven DTC approach delivers deep retention insight plus marketing efficiency that builds on itself over time. Prenetics isn't merely expanding. Our belief is that we're creating a new class of consumer company, one defined by execution discipline, scientific credibility and financial innovation; we hold $82 million in cash, $40 million in Bitcoin, a 35% stake in Insighta valued at $70 million based upon $0.10 investment, and a conservative $380 million valuation for the IM8 business. Our net asset value comes to roughly $572 million, or about $34 per share. Even so, I'm confident that over the coming years we'll turn into the multibillion-dollar company I picture, assisting millions of people worldwide with science-backed solutions for optimal health and longevity. With that said, I'll hand the call to our CFO, Stephen Lo, who will go through the financials in more detail.

Hoi Chun Lo executive
#3

Thanks, Danny, and good morning, everyone. We're glad to report that Q3 set a record, demonstrating the strength of our business model and its ability to scale. Danny just walked through most of the financials. Before I turn things over to the operator for Q&A, I want to touch on a few items. Let's begin with the improvement in adjusted EBITDA. The trend there keeps getting better — from a $4.5 million loss in Q1, back when ACT Genomics was still dragging on results, to $2.1 million in Q3. That reflects our operating leverage and a clear route to profitability. After the funding round in October and the sale of ACT Genomics, our cash position has climbed to about $80 million, while our Bitcoin holdings now stand at 387 BTC, valued at roughly $41 million. That puts our total liquidity at around $120 million, with no debt on our books. Thanks to this liquidity, we can scale IM8 worldwide, invest in marketing, and continue building our Bitcoin position within our dual engine framework. We're also lucky enough to be able to prioritize growth over near-term profitability, which allows us to grab the largest possible market share during this pivotal scaling period. As IM8 continues to deliver both scale and margin expansion, we can strengthen its position as our primary growth engine. We've put ourselves in a position to restate our guidance for the full year 2025, confirming revenue of $90 million to $100 million, and IM8 should come in at roughly $60 million. Looking at 2026, we anticipate IM8 revenue landing somewhere between $180 million and $200 million, fueled by ongoing growth in international markets, the introduction of new products, and stronger brand activation. Our priority stays fixed on scaling in an efficient way, growing margins, and keeping our financial discipline. Danny already noted that the third quarter marked yet another period of solid execution and strategic headway, which sets up Prenetics for lasting value creation through 2026 and afterward. Thanks to all of you for being here today. Operator, we're ready to take questions now.

Sheng Wu Yeung executive
#4

Sure, thanks. So we're really happy with a payback period of 3.9 months. For some context—you're all looking at this whole year from Hims & Hers, right? That's a company we really look up to, especially given they're a $10 billion market cap business. Their payback period comes in at about 12 months. And how do we figure out payback period? Basically, we take our customer acquisition cost and look at how long it takes to earn that acquisition cost back, based on our gross margins. That's how we arrive at 3.9 months. On the question of how things have changed over time: at the beginning, the payback period sat at around four to five months. Since then, I'd say we've achieved better marketing efficiency and accumulated far more data. Because that payback trend is moving downward, and because rivals are sitting somewhere between six and twelve months, even if we assume the worst — a five-to-six-month payback — we remain in an excellent position relative to how big players like Hims & Hers treat this metric, which, as I mentioned, ranks among the most important numbers any DTC business monitors right now. That's a solid question, isn't it? Alright, so looking back at the beginning — IM8 launched around December. During those initial two or three months, our U.S. share was sitting at approximately 70%. Since then, that figure has shifted to about 46.5% domestically, with 55.5% now coming from outside the States. The takeaway here is that in just 11 or 12 months, we've gone from nothing to a worldwide operation reaching 31 nations. Those 31 nations represent a worldwide market chance that we estimate at more than $700 billion in total addressable market. That tells us we're in a strong spot to expand across a great number of these markets. Growth is coming in from all over, too. Like I said, the U.S. leads the pack at #1. Canada's numbers are climbing, Europe's climbing, the Middle East is climbing, and Southeast Asia — Singapore, Hong Kong — is climbing as well. Basically, every market where we do business is showing gains. Yeah, good question. With the liquidity we have on hand right now, we don't anticipate needing to raise any fresh capital to pay for our expansion. And as we also said, for Q3 our adjusted EBITDA loss came in at only $2.1 million. Once more, for any DTC brand, landing in that kind of position is really something remarkable. So I believe we put in a great deal of effort behind the scenes on the operational side to make sure that once the first year wraps up, we can reach breakeven; that's what the metrics and data indicate; but then again, with the worldwide chance for expansion, we intend to pursue aggressive growth even more; and I think, too, to touch on the recent equity fundraising, the wonderful aspect of this raise is that there's a 50%, 100% premium warrant and we are reaching that share price, essentially, the first warrant can be exercised at $24, correct? And after that $32 at a far greater valuation, we will receive extra capital to keep financing this growth, right? To reiterate, we've set some really bold goals, and this latest round of fundraising gives us a lot of room to operate—so we can push for growth and keep losses in check at the same time, which is exactly what our Q2 numbers demonstrate. So yeah, when it comes to capital, we're sitting in a pretty strong spot, and we don't see any need to raise money right away. Thanks to all of you for being here. And again, this is our very first time doing an investor—sorry, an earnings call. Like I mentioned when we kicked things off, the reason is that we never really had anything we could honestly brag about or feel proud of. Still, my sense is that we're holding something truly extraordinary right now. You may be aware that I do a good deal of traveling, and yet wherever I go — in each nation, and with every person I meet there — it amazes me how large a share of the world's population is already on IM8 and weaving it into their daily habits. What we're creating here is remarkably unique, and I'm confident the market will catch on before long. I appreciate you staying with us on this ride, and you can count on hearing from me about our momentum and what lies in front of us.

Operator operator
#5

Everyone, we appreciate you joining us, and that brings today's conference call to a close. Please feel free to hang up your phones, and we hope the rest of your day is great.

For developers and AI pipelines

Programmatic access to Prenetics Global Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.